This product includes the webinar and SAM credit.


This webinar reviews the updated diagnostic criteria of myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms according to the recently revised WHO Classification, with emphasis on significant changes from the prior (2008) WHO Classification. New and revised entities within this group of diseases will be presented and the appropriate testing required to correctly diagnose these neoplasms will be discussed.

Speaker: Robert P. Hasserjian, MD

Host: Jennifer Dunlap, MD

Duration: 1 hr

Level of Instruction: Basic

Last day to purchase course and claim credit: February 15, 2021

Maximum CME/CMLE credit available: 1.0

How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.

This course is approved by the American Board of Pathology for 1.0 SAM credits.Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

* You may not submit SAMs and CME/CMLE credit for the same content.

You may also be interested in:

Note: Join the AMP Family to purchase this content for a deep discount!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
February 15, 2018
Course Objectives
  • Describe the criteria for establishing a primary diagnosis of myelodysplastic syndrome.
  • Distinguish between the subtypes of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms according to current criteria in the 2016 WHO Classification.
  • Employ ancillary testing (including flow cytometry, immunohistochemistry, cytogenetics, and molecular genetic testing) effectively in the diagnosis, classification, and prognostication of myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
WHO Update 2016: Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Speaker Information
Robert P. Hasserjian MD   [ view bio ]
Individual topic purchase: Selected
American Board of Pathology
Self-Assessment Module: 1.00
Hasserjian Presentatin (+SAM)
AMP Regular Member: $10.00
AMP Technologist Member: $10.00
AMP Associate Member: $10.00
Non-member Price: $215.00